Results of a randomized phase III trial indicate that the kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo. The trial will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4). If approved for use in thyroid ...Tuesday, 4 June 2013
Sorafenib Shows Promise in Treating Advanced Differentiated Thyroid Cancer Patients
Results of a randomized phase III trial indicate that the kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo. The trial will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4). If approved for use in thyroid ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment